Label update for diabetes drug liraglutide to include prevention of cardiovascular events

The European Commission has approved an update to the liraglutide (Victoza) EU label that expands the indication to reflect both improving blood sugar and cardiovascular (CV) events as integral parts of type 2 diabetes treatment. Liraglutide is the only GLP-1 that is proven to prevent CV events in people with type 2 diabetes and high CV risk. The updated label includes results from the LEADER trial, which demonstrated that liraglutide statistically significantly reduced the risk of cardiovascular death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13% versus placebo, when added to standard of care. The overall risk reduction was derived from